ABX464 Phase 2a ulcerative colitis two-year maintenance study results confirm good safety profile and durable efficacy of 50 mg once-daily oral ABX464
77% (180/232) of patients randomized in ABX464 Phase 2b ulcerative colitis study, recruitment expected to be completed by the end of 2020
ABX464 pivotal Phase 2b/3 trial for Crohn’s disease planned with anticipated start of patient recruitment in Q1 2021
ABX464 Phase 2b/3 Covid-19 study, ABX464 Phase 2a rheumatoid arthritis study and ABX196 Phase 1/2 hepatocellular carcinoma trial all making progress
Cash for operations until beginning 2021, with major financing secured through non-dilutive funding from Bpifrance (EUR 36m) and a state-guaranteed loan from Société Générale (EUR 5m)
